Related Experiment Video
Updated: Jun 28, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines
Michela Di Michele1, Anna Della Corte, Lucia Cicchillitti
1John Paul II Centre for High Technology Researches and Education in Biomedical Sciences, Catholic University, Campobasso, Italy. michela.dimichele@moli-sani.org
Abstract:
Ovarian cancer is the leading cause of gynaecological cancer mortality. Paclitaxel is used in the first line treatment of ovarian cancer, but acquired resistance represents the most important clinical problem and a major obstacle to a successful therapy. Several mechanisms have been implicated in paclitaxel resistance, however this process has not yet been fully explained. To better understand molecular resistance mechanisms, a comparative proteomic approach was undertaken on the human epithelial ovarian cancer cell lines A2780 (paclitaxel sensitive), A2780TC1 and OVCAR3 (acquired and inherently resistant). Proteins associated with chemoresistance process were identified by DIGE coupled with mass spectrometry (MALDI-TOF and LC-MS/MS). Out of the 172 differentially expressed proteins in pairwise comparisons among the three cell lines, 151 were identified and grouped into ten main functional classes. Most of the proteins were related to the category of stress response (24%), metabolism (22%), protein biosynthesis (15%) and cell cycle and apoptosis (11%), suggesting that alterations of those processes might be involved in paclitaxel resistance mechanisms. This is the first direct proteomic comparison of paclitaxel sensitive and resistant ovarian cancer cells and may be useful for further studies of resistance mechanisms and screening of resistance biomarkers for the development of tailored therapeutic strategies.
Insights
Paclitaxel resistance in ovarian cancer is a major challenge. This study identified key proteins involved in chemoresistance, offering insights into developing targeted therapies for ovarian cancer.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- Ovarian cancer is a leading cause of gynecological cancer mortality.
- Paclitaxel is a first-line treatment, but acquired resistance limits its efficacy.
- Mechanisms of paclitaxel resistance in ovarian cancer are not fully understood.
Purpose of the Study:
- To investigate the molecular mechanisms underlying paclitaxel resistance in ovarian cancer.
- To identify proteins associated with chemoresistance using a comparative proteomic approach.
- To compare protein expression profiles in paclitaxel-sensitive and resistant ovarian cancer cell lines.
Main Methods:
- Comparative proteomic analysis using Difference Gel Electrophoresis (DIGE).
- Protein identification via mass spectrometry (MALDI-TOF and LC-MS/MS).
- Utilized paclitaxel-sensitive (A2780) and resistant (A2780TC1, OVCAR3) human epithelial ovarian cancer cell lines.
Main Results:
- Identified 151 differentially expressed proteins out of 172 detected.
- Proteins were categorized into ten functional classes, with stress response (24%), metabolism (22%), protein biosynthesis (15%), and cell cycle/apoptosis (11%) being most prominent.
- This study provides the first direct proteomic comparison of paclitaxel-sensitive and resistant ovarian cancer cells.
Conclusions:
- Alterations in stress response, metabolism, protein biosynthesis, and cell cycle/apoptosis pathways are likely involved in paclitaxel resistance.
- The identified proteins may serve as potential biomarkers for predicting or overcoming chemoresistance.
- Findings support further research into resistance mechanisms and the development of tailored therapeutic strategies for ovarian cancer.
